SRNE News and Press, Sorrento Therapeutics Inc. From 03/02/22

FDA granted IND clearance today for STI-9199 (COVISHIELD ™ ) for a Phase 1 safety and pharmacokinetic study in healthy volunteers. Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients. STI-9199 has d...

Sorrento Therapeutics (SRNE +0.5%) said additional preclinical results showed broad spectrum COVISHIELD (STI-9167) neutralizing activity against Omicron BA.1, Omicron BA.1+R346K, and the increasingly prevalent sublineage, Omicron BA.2. The company added that an investigational new drug a...

STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses, including Omicron BA.1 (+R346K mutation). An IND application for COVISHIELD™ ...

Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary –  PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread...

Sorrento Therapeutics (NASDAQ:SRNE) announced the acquisition of Chinese-based diagnostic test maker, Zhengzhou Fortune Bioscience as the company plans to ramp up the production of its COVISTIX COVID-19 VIRUS Rapid Antigen Detection Test. The deal includes an option for Sorrento (SRNE) to acq...

COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant. COVISTIX has an enhanced sensitivity in detecting the Omicron variant with a more than 10-fold lower limit of detection (LoD) as comp...

Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform (“Virex Technology”). Virex Technology, invented and developed by Boston University (BU) Professors Mark Grinstaff and Scott Schaus and Vir...

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) (NASDAQ:SRNE) into potential breaches of fiduciary duty by the Company’s Board of Dir...

STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans. SAN DIEGO, Jan. 28, 2022 (GL...

Shares of clinical- and commercial-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) plummeted by a whopping 36.8% during the first four trading sessions this week, according to data provided by S&P Global Market Intelligence . As the biotech hasn't had any clinical or re...